Baixius

Baixius (Beijing) Biotechnology is a Chinese biopharmaceutical company focused on the development of innovative adeno-associated virus (AAV) based gene therapies for rare genetic disorders. The company leverages its proprietary AAV vector platform to design high-efficiency delivery systems targeting specific tissues, with a primary focus on hematological conditions such as Hemophilia A and B. Baixius aims to provide one-time curative treatments that restore the production of essential clotting factors in patients. Currently in the pre-clinical stage, the company is advancing its pipeline through rigorous validation of its capsid engineering and manufacturing processes. Baixius is positioned within the growing landscape of Chinese gene therapy innovators seeking to address unmet medical needs in the rare disease space.